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Summary
 
The induction of type 1 immune responses (interleukin [IL]-12, interferon [IFN]-
 
g
 
) has been
shown to be important in mediating protection against many intracellular infections including
 
Histoplasma capsulatum.
 
 Costimulatory molecules such as CD40 ligand (CD40L) have been
shown to be a central regulator of type 1 responses in vivo. To study the role of CD40L in me-
diating protection against infection with 
 
H. capsulatum
 
, CD40L-deficient (CD40L
 
2
 
/
 
2
 
) and
CD40L
 
1
 
/
 
1
 
 mice were infected with 
 
H. capsulatum
 
 and assessed for various parameters. After a
lethal challenge of 
 
H. capsulatum
 
, CD40L
 
2
 
/
 
2
 
 mice were not substantially different from
CD40L
 
1
 
/
 
1
 
 mice in terms of mortality, fungal burden, or production of IFN-
 
g
 
, IL-12, nitric
oxide, or tumor necrosis factor 
 
a
 
. Moreover, CD40L
 
2
 
/
 
2
 
 mice treated with anti–IFN-
 
g
 
 or
anti–IL-12 at the time of infection had accelerated mortality, providing further evidence that
IL-12 and IFN-
 
g
 
 are produced in vivo in the absence of CD40L. In addition, CD40L
 
2
 
/
 
2
 
 mice
infected with a sublethal dose of 
 
H. capsulatum
 
 survived infection, whereas all mice infected
with the same dose and treated with anti–IFN-
 
g
 
 had accelerated mortality, demonstrating that
IFN-
 
g
 
 but not CD40L was essential for primary immunity to 
 
H. capsulatum
 
 infection. Interest-
ingly, depletion of either CD4
 
1
 
 or CD8
 
1
 
 T cells resulted in accelerated mortality in CD40L
 
2
 
/
 
2
 
mice, suggesting a critical role for these cells in response to infection. Finally, CD40L
 
2
 
/
 
2
 
 mice
initially infected with a sublethal dose of 
 
H. capsulatum
 
 were protected from secondary infec-
tion with a lethal dose of 
 
H. capsulatum
 
, demonstrating that CD40L is not required for the
maintenance of memory immunity.
 
T
 
he role of CD40L–CD40 costimulation in mediating
T cell responses in vivo was first shown in studies us-
ing CD40L-deficient (CD40L
 
2
 
/
 
2
 
) mice. In these studies, T
cell activation and production of cytokines such as IFN-
 
g
 
were markedly impaired in response to protein antigens in
vivo (1). This ability of CD40L–CD40 stimulation to regu-
late Th1 (IFN-
 
g
 
) or type 1 (IFN-
 
g
 
, IL-12) cytokine re-
sponses in vivo was subsequently shown to occur through
at least two mechanisms (2), the first through the induction
of IL-12 from APCs such as macrophages and dendritic
cells (2–6) and the second by the ability of CD40L–CD40
stimulation to enhance expression of costimulatory cell sur-
face molecules (e.g., B7-1, B7-2) on APCs, leading to in-
creased T cell stimulation and production of IFN-
 
g
 
 (7–13).
Based on these data, since CD40L–CD40 costimulation
appears to be a key regulator of CD4
 
1
 
 T cell–mediated
type 1 responses in vivo, the role and mechanism by which
CD40L regulates immunity to infectious pathogens is of
great interest.
The first studies to examine the role of CD40L in regu-
lating immune responses to infection were done using mu-
rine models of parasitic and viral infections. In studies of vi-
ral infection, CD40L
 
2
 
/
 
2
 
 mice exposed to lymphocytic
choriomeningitis virus had normal primary CTL responses
with clearance of infection (14–16); however, memory
CTL responses were impaired, suggesting that CD40L was
important in maintaining a memory cellular (CTL) re-
sponse (14). With regard to the role of CD40L in an infec-
tious model requiring type 1 cytokine production, a series
of studies were done using the well-established murine
model of 
 
Leishmania
 
 infection (17–19). In these experi-
ments, CD40
 
2
 
/
 
2
 
 or CD40L
 
2
 
/
 
2
 
 mice on a resistant back-
ground were markedly impaired in production of IL-12
(17) and IFN-
 
g
 
 (17–19), correlating with enhanced suscep-
tibility to infection (17, 19) or exacerbation of infection (18).
The aforementioned studies provided strong evidence
that CD40L–CD40 interactions were important in mediat-
ing CD4
 
1
 
 T cell–dependent production of IL-12 to either
protein antigens or 
 
Leishmania
 
 infection in vivo; however,
DeKruyff et al. then showed a CD40L-independent path-
 
1
 
Abbreviations used in this paper:
 
 CD40L, CD40 ligand; NO, nitric oxide.
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way for IL-12 production from mononuclear cells stimu-
lated in vitro with either LPS or heat-killed 
 
Listeria monocy-
togenes
 
 (20). These latter data suggested that certain intracellular
pathogens can directly induce IL-12 in vitro and raised the
question as to whether these or other pathogens would
elicit functional type 1 immune responses in vivo in the ab-
sence of CD40L.
In this report, we addressed the role of CD40L in regu-
lating type 1 cytokine responses in vivo using a murine
model of disseminated histoplasmosis. 
 
Histoplasma capsula-
tum
 
 is a dimorphic fungus found in the soil in distinct geo-
graphic regions around the world. Primary infection occur-
ring through inhalation of conidial or mycelial fragments
often results in a self-limited upper respiratory infection in
immunocompetent hosts. By contrast, in immunocompro-
mised hosts, disseminated infection can occur in multiple
organs either through primary infection as described above
or by recurrence of a previous infection (21–23). Protective
immunity is achieved by the interaction of T cells and mac-
rophages through the generation of a type 1 immune re-
sponse characterized by production of IL-12 leading to
IFN-
 
g
 
 induction (24, 25). Additional factors such as TNF-
 
a
 
and nitric oxide have also been shown to be important in
mediating protection against primary infection (26). The
studies presented here examined the role of CD40L in the
generation of an immune response after both primary and
secondary infection with 
 
H. capsulatum
 
 using CD40L
 
2
 
/
 
2
 
mice. The results show that CD40L
 
2
 
/
 
2
 
 mice are not sub-
stantially different from CD40L
 
1
 
/
 
1
 
 mice in terms of mor-
tality, fungal burden, or the ability to develop a functional
type 1 cytokine response in vivo compared with control
CD40L
 
1
 
/
 
1
 
 mice after infection with 
 
H. capsulatum.
 
 Fur-
thermore, although both CD40L
 
2
 
/
 
2
 
 and CD40L
 
1
 
/
 
1
 
 mice
infected with a sublethal dose of 
 
H. capsulatum
 
 survived in-
fection and developed sterilizing immunity, all mice in-
fected with the same dose and treated with anti–IFN-
 
g
 
 at
the time of infection had accelerated mortality. These data
provide clear evidence that IFN-
 
g
 
 but not CD40L is essential
for protective immunity to primary 
 
H. capsulatum
 
 infection.
Finally, of interest was the observation that CD40L
 
2
 
/
 
2
 
 mice
depleted of either CD4
 
1
 
 or CD8
 
1
 
 T cells had accelerated
mortality and increased fungal burden after primary infec-
tion. Overall, these studies demonstrate that CD40L
 
2
 
/
 
2
 
mice develop relatively intact type 1 cytokine responses to
 
H. capsulatum
 
 and suggest a differential requirement for
CD40L in the generation of this type of immune responses
after infection to 
 
H. capsulatum
 
 versus 
 
Leishmania major.
 
Materials and Methods
 
Mice and Infection.
 
CD40L
 
2
 
/
 
2
 
 mice generated on C57BL/6J
 
3
 
 129/J background (27) were obtained from The Jackson Labo-
ratory (Bar Harbor, ME). As a control, C57BL/6 
 
3
 
 129(F2), also
purchased from The Jackson Laboratory, were used and desig-
nated as CD40L
 
1
 
/
 
1
 
 mice. In some experiments, CD40L
 
2
 
/
 
2
 
 mice
obtained from Immunex (Seattle, WA) were bred on a C57BL/6
background (greater than six generations). Virus-free female
C57BL/6 mice purchased from Division of Cancer Treatment,
National Cancer Institute (Frederick, MD) were used as controls
for these experiments. In all experiments, mice were between 5
and 10 wk of age. Mice were inoculated intravenously in 0.5 ml
sterile PBS with varying doses of 
 
H. capsulatum
 
 yeast cells. In one
experiment, CD40L
 
2
 
/
 
2
 
 mice were challenged with 10
 
5
 
 metacy-
clic promastigotes 
 
L. major
 
 (WHOM/IR/-/173) in their hind
footpads as previously described (28). Weekly footpad swelling
measurements were recorded using a caliper.
 
Media.
 
HBSS (Biofluids, Inc., Rockville, MD) was used as a
wash medium. Complete medium: RPMI 1640 (Biofluids, Inc.)
supplemented with 10% fetal bovine serum (Biofluids, Inc.), pen-
icillin (100 U/ml), streptomycin (100 
 
m
 
g/ml), 
 
l
 
-glutamine (2
mM), sodium pyruvate (1 mM), and 2-ME (0.05 mM) was used
for culturing spleen cells.
 
Preparation and Quantitation of H. capsulatum.
 
The yeast phase
of 
 
H. capsulatum
 
 (strain GS-57) was used in all experiments, and
quantitation of 
 
H. capsulatum
 
 was performed as previously de-
scribed (26). In brief, spleens from mice infected with 
 
H. capsula-
tum
 
 and/or treated with various cytokine antagonists were killed
at various times after infection. In most experiments, three indi-
vidual spleens from each group were quantitated for CFUs. In
some experiments, one-third of each spleen from two or three
individual animals in each group were combined and homoge-
nized in a sterile mortar using PBS to prepare a 1:10 wt/vol sus-
pension. 10-fold dilutions in PBS were plated in duplicate at 0.05
ml/plate on BHI-SAGC medium and incubated for 7 d at 30
 
8
 
C.
Colonies were enumerated and the counts were recorded as CFUs.
 
In Vivo Treatment of Mice.
 
Most antibodies were purified from
ascites by ammonium sulfate precipitation. Rat anti–mouse IFN-
 
g
 
mAb (XMG1.2; reference 29), anti-CD4 (GK1.5; reference 30),
and anti-CD8 (2.43; reference 31) were used to neutralize IFN-
 
g
 
and to deplete CD4
 
1
 
 and CD8
 
1
 
 T cells, respectively. Purified
mAbs against murine IL-12 (C17.8; reference 32) were obtained
from Dr. Giorgio Trinchieri (Wistar Institute, Philadelphia, PA)
and have been shown to be effective in neutralizing IL-12 in vivo.
Mice were injected with anti–IFN-
 
g
 
 (1 mg) intraperitoneally at the
time of primary infection. Anti-CD4 and anti-CD8 antibodies
were injected 3 d before, at the time of, and 5–7 d after infection.
This treatment resulted in a 
 
.
 
95% depletion of CD4
 
1
 
 or CD8
 
1
 
T cells from spleen at 1 wk after infection, as assessed by FACS
 
Ò
 
.
 
Cytokine mRNA Measurement.
 
Cytokine mRNA levels were
determined by semiquantitative reverse transcription PCR tech-
niques as previously described (26). In brief, total RNA was iso-
lated from spleen cells by resuspending in RNAzol B (Tel-Test,
Friendswood, TX) and recovering the aqueous phage after addi-
tion of chloroform. RNA was precipitated with alcohol and re-
suspended in RNase-free H
 
2
 
O. Total RNA (1 mg) was reverse
transcribed by Moloney murine leukemia virus reverse tran-
scriptase (GIBCO BRL, Gaithersburg, MD). The reaction mix-
ture was then diluted 1:8, and 10 ml was used for specific semi-
quantitative amplification of cytokine mRNA with Taq DNA
polymerase (Promega, Madison, WI) and specific cytokine sense
and antisense primers. The number of amplification cycles was
as follows: 24 (hypoxanthine phosphoribosyltransferase), 25
(IFN-g), 29 (IL-12 p40), and 33 (NO and TNF-a). Southern
transfers of PCR products were subsequently probed with inter-
nal cytokine-specific oligonucleotides and visualized using the
ECL chemiluminescent detection system (Amersham Corp., Ar-
lington Heights, IL).
Statistics. Statistical evaluation of differences between means
of experimental groups was done by analyses of variance and
multiple Student’s t tests. The log-rank was used for statistical 
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analysis of mortality. A value of 
 
P
 
 
 
,
 
0.05 was considered to be
significant.
 
Results
 
CD40L
 
2
 
/
 
2
 
 Mice Are More Susceptible to Infection with L.
major but Not H. capsulatum Compared with CD40L
 
1
 
/
 
1
 
Mice.
 
Recent work by several groups has shown that
CD40
 
2
 
/
 
2
 
 or CD40L
 
2
 
/
 
2
 
 mice were susceptible to 
 
Leishma-
nia
 
 infection due to diminished production of type 1 cy-
tokines (17–19). In other studies, mice infected with 
 
H.
capsulatum
 
 (6 
 
3
 
 10
 
5
 
) and treated with anti–IL-12 or anti–
IFN-
 
g
 
 have accelerated mortality, demonstrating a critical
role for these cytokines in primary infection to 
 
H. capsula-
tum
 
 (24, 25). Thus, the role of CD40L in mediating pro-
tective immunity and the generation of type 1 cytokine
production in response to 
 
H. capsulatum
 
 infection was eval-
uated. As shown in Fig. 1 
 
A
 
, the rate at which CD40L
 
2
 
/
 
2
 
mice succumbed to infection (14.67 
 
6
 
 3.82 d) was not dif-
ferent than that for CD40L
 
1
 
/
 
1
 
 mice (14.75 
 
6
 
 3.84 d). By
contrast, in the same experiment, CD40L
 
2
 
/
 
2
 
 mice infected
with 
 
L. major
 
 were found to be susceptible to infection
compared with control CD40L
 
1
 
/
 
1
 
 mice (Fig. 1 
 
B
 
). These
data suggest that CD40–CD40L stimulation, although es-
sential for induction of type 1 responses to 
 
L. major
 
 (17–19),
may not be required for eliciting type 1 cytokine responses
to 
 
H. capsulatum.
CD40L
 
2
 
/
 
2
 
 Mice on a C57BL/6 
 
3
 
 129 Background Are
Resistant to Sublethal Infection with H. capsulatum.
 
In addi-
tion to the experiments shown above using CD40L
 
2
 
/
 
2
 
mice bred several generations (greater than six) onto a
C57BL/6 background, a series of experiments using
CD40L
 
2
 
/
 
2
 
 mice on a C57BL/6 
 
3
 
 129 background were
initiated. It should be noted that in these experiments, the
control CD40L
 
1
 
/
 
1
 
 mice are C57BL/6 
 
3
 
 129(F2), approx-
imating the background of the CD40L
 
2
 
/
 
2
 
 mice. As shown
in Fig. 2 in data combined from two independent experi-
ments, infection of CD40L
 
2
 
/
 
2
 
 mice with 
 
H. capsulatum
 
(6 
 
3
 
 10
 
5
 
) showed a modest but not statistically significant
increase in the rate of mortality (35.6 
 
6
 
 20.4 d) compared
with the control CD40L
 
1
 
/
 
1
 
 mice (41.5 
 
6
 
 21.3 d). In addi-
tion, all mice infected with a sublethal dose (6 
 
3
 
 10
 
4
 
 or 6 
 
3
 
10
 
3
 
) survived infection. Thus, these data support a CD40L-
independent role in protective immunity.
 
Quantitative Burden of H. capsulatum in CD40L
 
2
 
/
 
2
 
 and
CD40L
 
1
 
/
 
1
 
 Mice on Different Backgrounds.
 
To correlate
whether the fatal outcome shown above was due to an in-
crease in the infectious burden of 
 
H. capsulatum
 
, quantita-
tive cultures were set up from spleen cells at various times
after infection. In the same experiment as shown in Fig. 2,
spleen cells of mice were harvested 7 d after infection and
CFUs for 
 
H. capsulatum
 
 were determined (Table 1).
CD40L
 
2
 
/
 
2
 
 mice infected with 6 
 
3
 
 10
 
5
 
 yeast cells had a
twofold increase in infectious burden at 7 d after infection
compared with control mice. Furthermore, CD40L
 
2
 
/
 
2
 
mice infected with lower doses (6 
 
3
 
 10
 
4
 
, 6 
 
3
 
 10
 
3
 
) had al-
most identical CFUs for 
 
H. capsulatum
 
 compared with con-
trol mice. These data further support the contention that
CD40L is dispensable for this infection.
 
CD40L
 
2
 
/
 
2
 
 Mice Have Similar mRNA Expression of Inflam-
matory Cytokines as Do CD40L
 
1
 
/
 
1
 
 Mice.
 
In the studies ex-
Figure 1. CD40L2/2 mice on a C57BL/6 background are more sus-
ceptible to infection with L. major but not H. capsulatum compared with
CD40L1/1 mice. (A) CD40L2/2 or CD40L1/1 mice (6–10 mice/group)
on a C57BL/6 background were injected intravenously with H. capsula-
tum yeast cells (6 3 105) and followed for mortality. (B) In a parallel ex-
periment, CD40L2/2 and CD40L1/1 mice were challenged in the hind
footpad with 105 live L. major metacyclic promastigotes. Weekly footpad
measurements represent the average footpad scores 6 SEM. Similar re-
sults were noted in a second experiment.
Figure 2. CD40L2/2 mice are resistant to sublethal infection with H.
capsulatum. CD40L2/2 or CD40L1/1 mice (4–6 mice/group) on a
C57BL/6  3 129 background were injected intravenously with varying
doses of H. capsulatum yeast cells (6 3 105, 6 3 104, 6 3 103) and fol-
lowed for mortality. Results are combined from two individual experi-
ments.
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amining cytokine production in CD402/2 or CD40L2/2
mice in response to leishmanial infection, it was clear that
there was a marked deficiency in production of IFN-g
(17–19), IL-12 (17, 19), and nitric oxide (NO) (18). To
determine whether any qualitative or quantitative changes
in cytokine production occurred in CD40L2/2 mice com-
pared with control CD40L1/1 mice after H. capsulatum in-
fection, mRNA expression for several cytokines previously
found to be important in regulating primary immunity to
H. capsulatum was assessed by semiquantitative PCR at var-
ious time points after infection. As shown in Fig. 3,
mRNA for IFN-g, IL-12 p40, and TNF-a were expressed
from spleen cells of CD40L2/2 and CD40L1/1 mice 7 and
20 d after infection with any of the doses tested. In addi-
tion, mRNA for NO was expressed from both types of
mice 7 d after infection. As a control, there was minimal
mRNA expression for any of the cytokines from spleen
cells of uninfected mice prepared at day 7 after infection.
Thus, these data confirm that type 1 cytokines are induced
in CD40L2/2 mice after infection with H. capsulatum. Fi-
nally, it should be noted that similar amounts (4–7 ng/ml)
of IL-12 protein (p40 1 p70) were detected from serum 3
and 7 d after infection from both CD40L2/2 and CD40L1/1
mice (data not shown).
In Vivo Depletion of IFN-g or IL-12 Results in Accelerated
Mortality in CD40L2/2 Mice in Response to Infection with H.
capsulatum. The data shown above suggest that CD40L2/2
and CD40L1/1 mice induce comparable type 1 immune
responses that might provide some immunity against a le-
thal challenge with H. capsulatum. Functional evidence
showing that CD40L2/2 mice are capable of producing
IL-12 and IFN-g in vivo was demonstrated by treating
mice with neutralizing antibodies against IL-12 or IFN-g at
the time of infection and assessing their outcome. As shown
in Fig. 4, CD40L2/2 mice treated with either anti–IL-12
(8.6 6 1.3 d) or anti–IFN-g (8.8 6 1.1 d) had accelerated
mortality compared with mice infected with only CD40L2/2
(31.0 6 15.1 d; P ,0.05). Similar results were seen from
CD40L1/1 mice after infection. Neutralization of IL-12 or
IFN-g also resulted in a 3–10-fold increase in infectious
burden of H. capsulatum compared with infected-only mice
(P  ,0.001), providing further evidence that CD40L2/2
mice are capable of making IL-12 and IFN-g in vivo.
CD40L Is Not Required for Protective Immunity against H.
capsulatum. Although CD40L2/2 mice had similar out-
comes to control mice infected with a lethal dose of H. cap-
sulatum, most of them still succumbed to infection. By con-
trast, as demonstrated in Fig. 2, CD40L2/2 mice infected
with 6 3 104 yeast cells were able to control infection, sug-
gesting that CD40L is not essential for protective immunity
at this infective dose. Since we had shown in a previous
study that IFN-g2/2 mice infected with 6 3 104 or 6 3
103 yeast cells succumbed to infection (26), the relative dis-
Figure 3. CD40L2/2 mice
have similar mRNA expression
for type 1 cytokines as CD40L1/1
mice. mRNA was isolated from
spleen cells combined from three
individual spleens of mice at 7
and 20 d after primary infection
with H. capsulatum. As a control,
mRNA was prepared from unin-
fected mice at 7 d after infection.
Cytokine mRNA was subse-
quently determined for IFN-g,
IL-12 p40, TNF-a, and NO by
semiquantitative reverse tran-
scription PCR as described in
Materials and Methods. N.D.,
not done.
Table 1. Quantitative Burden of H. capsulatum in CD40L2/2 
and CD40L1/1 Mice After Primary Infection*
H. capsulatum, day 7
CFUs
CD40L2/2 (C57BL/6 3 129)
HC 6 3 105 3.3 3 106 6 0.18 3 106
HC 6 3 104 6.5 3 105 6 0.21 3 105
HC 6 3 103 3.5 3 105 6 1.21 3 105‡
CD40L1/1 (C57BL/6 3 129)
HC 6 3 105 1.4 3 106 6 0.12 3 106
HC 6 3 104 6.7 3 105 6 0.12 3 105
HC 6 3 103 2.7 3 105 6 0.35 3 105‡
*Mice were infected with H. capsulatum with various doses (6 3 105, 6 3
104, or 6 3 103), and quantitative burden of H. capsulatum from spleen
cells of individual mice (n 5 3) were determined 7 d after infection as
described in Materials and Methods. 1 wk later, colonies were counted
as CFUs.
‡Results are statistically different (P ,0.001) from those of mice in-
fected with H. capsulatum (6 3 105).1319 Zhou et al.
pensability of CD40L compared with IFN-g in developing
effective immunity against primary infection with a suble-
thal dose of H. capsulatum (6 3 104) was assessed. As shown
in Fig. 5, all CD40L2/2 and CD40L1/1 mice survived in-
fection with 6 3 104 yeast cells, whereas all mice treated
with anti–IFN-g had a fatal outcome with accelerated
mortality. These experiments show conclusively that effec-
tive primary immunity to H. capsulatum occurs in an IFN-
g–dependent, CD40L-independent manner.
In the Absence of CD40L, CD41 or CD81 T Cells Are Re-
quired for Effective Immunity to Infection with H. capsulatum.
Both CD41 and CD81 T cells have been shown to be im-
portant in primary immunity against H. capsulatum (33, 34).
To assess the role of CD41 and CD81 T cells in CD40L2/2
mice infected with H. capsulatum, animals were treated
with antibodies against CD41 and CD81 T cells before, at
the time of, and after infection to ensure depletion (.95%
by FACSÒ). As shown in Fig. 6 in data combined from two
independent experiments, depletion of either CD41 (12.8
6 0.9 d) or CD81 T cells (12.3 6 0.05 d) caused acceler-
ated mortality compared with infected controls (34.8 6
19.6 d). This increase in mortality was associated with a
three- to fourfold increase in CFUs for H. capsulatum from
spleen cells of mice depleted of either CD41 or CD81 T
cells (P ,0.001). Thus, in the absence of CD40L, CD41 or
CD81 T cells play a critical role in protective immunity.
CD40L Is Not Required for Protective Immunity after Second-
ary Infection to H. capsulatum. One final aspect of these
studies was to examine the requirement for CD40L in a
memory or secondary immune response to H. capsulatum.
To assess the role of CD40L2/2 in the maintenance of im-
munity after secondary infection, CD40L2/2 mice were
Figure 4. Neutralization of endogenous IFN-g or IL-12 results in ac-
celerated mortality in CD40L2/2 and CD40L1/1 mice after infection
with H. capsulatum. CD40L2/2 and CD401/1 (C57BL/6 3 129) mice
(4–6 mice/group) were injected intravenously with H. capsulatum yeast
cells (6 3 105) and followed for mortality. Additional groups of mice
were treated with anti–IFN-g (1 mg) or anti–IL-12 (1 mg) at the time of
reinfection. Results are combined from two independent experiments.
To assess quantitative burden of H. capsulatum, mice were killed 7 d after
infection, and spleen cells from individual mice (n 5 3) were plated at
various concentrations on agar plates as described in Materials and Meth-
ods. 1 wk later, colonies were counted as CFUs. Asterisk indicates that re-
sults are statistically different (P ,0.001) from those of mice infected with
H. capsulatum alone.
Figure 5. IFN-g but not CD40L is required for protective immunity
after sublethal infection to H. capsulatum. CD40L2/2 and CD40L1/1
mice on a C57BL/6 3 129 or C57BL/6 background were infected intra-
venously with a sublethal dose of H. capsulatum yeast cells (6 3 104) and
treated with anti–IFN-g (1 mg) at the time of infection. Mice were fol-
lowed for mortality.
Figure 6. CD4 or CD81 T cells are required for effective immunity to
H. capsulatum infection in CD40L2/2 mice. In results combined from two
independent experiments, CD40L2/2 and CD40L1/1 mice (4–6 mice/
group) intravenously infected with H. capsulatum yeast cells (6 3 105)
were treated with anti-CD4 (1 mg) or anti-CD8 (1 mg) 3 d before, at the
time of, and 5–7 days after infection and were followed for mortality.
Quantitative burden of H. capsulatum was assessed as described in Fig. 4.
Similar results were noted in a second experiment.1320 CD40 Ligand Is Not Required for Th1 Responses In Vivo to Infection
initially infected with a sublethal dose of H. capsulatum (6 3
104) and then reinfected 3–4 wk later with a lethal dose (6 3
105). As shown in Fig. 7 in data combined from two inde-
pendent experiments, all CD40L2/2 mice reinfected with a
lethal dose (6 3 105) survived and remained healthy up to
120 d after infection. As a control, a majority of the
CD40L2/2mice undergoing primary infection (6 3 105) at
the same time succumbed within 20–30 d, consistent with
the data shown in the previous figures.
To determine whether effective immunity to a second-
ary challenge was due to control of H. capsulatum in vivo,
the infectious burden of H. capsulatum was assessed from
spleen cells at various time points after reinfection. Mice
originally infected with 6 3 104 yeast cells had low but de-
tectable amounts of H. capsulatum at the time of reinfection
(day 0) in one of the experiments (Table 2, Exp. 1) and no
detectable amounts in the other experiment (Table 2, Exp.
2). When assessed 7 d after reinfection, previously infected
CD40L2/2 mice had a 3-log reduction (P ,0.001) in H.
capsulatum compared with CD40L2/2 mice undergoing
primary infection (Table 2, Exp. 2) at the same time.
Moreover, in neither experiment was there any H. capsula-
tum detected from spleen cells at 60 or 90 d after reinfec-
tion, demonstrating that CD40L2/2 is not essential for the
development of sterilizing immunity after reinfection.
Discussion
CD40L Is Not Essential for Effective Primary Immunity to
H. capsulatum. CD40L–CD40 interactions have a central
role in the induction of humoral and cellular immune re-
sponses (35, 36). With regard to its effects on the cellular
immune response, CD40L–CD40 induction of inflamma-
tory cytokines and costimulatory molecules from macro-
phages and dendritic cells has been shown to enhance the
cellular immune response with production of type 1 cyto-
kines (35). Since IL-12–dependent production of IFN-g was
shown to be essential for protective immunity after primary
infection to the intracellular fungi H. capsulatum (24), it was
of interest to determine the requirement for CD40L in the
generation of type 1 cytokine responses after primary and
secondary infection with H. capsulatum. The initial experi-
ments using CD40L2/2 mice bred onto a C57BL/6 back-
ground (.6 generations) showed that they did not have ac-
celerated mortality or increased fungal burden (data not shown)
compared with CD40L1/1 mice (Fig. 1). In several addi-
tional experiments using CD40L2/2 mice on a C57BL/6 3
129 background, there did appear to be a modest increase
in the rate of mortality (Figs. 2 and 4) and the fungal bur-
den (Table 1) compared with the control CD40L1/1 mice
in response to a lethal dose (6 3 105 yeast) of H. capsulatum.
However, it should be noted that CD40L2/2 or CD40L1/1
mice infected with a sublethal amount of H. capsulatum (6 3
104) had identical outcomes. Furthermore, the data show-
ing that mRNA for IL-12, IFN-g, TNF-a, and NO are
similar between the CD40L2/2 and CD40L1/1 mice,
combined with the fact that in vivo neutralization with
anti–IFN-g or anti–IL-12 caused accelerated mortality and
Figure 7. CD40L is not required for effective immunity after second-
ary infection with a lethal challenge of H. capsulatum. In results combined
from two independent experiments, CD40L2/2 mice initially were in-
fected intravenously with 6 3 104 yeast cells and then reinfected (second-
ary infection) 3 wk later with H. capsulatum yeast cells (6 3 105). As a
control, CD40L2/2 mice were infected primarily with 6 3 105 yeast cells
at the same time mice were undergoing secondary infection.
Table 2. CD40L2/2 Mice Develop Sterilizing Immunity after a Secondary Challenge with H. capsulatum*
H. capsulatum (CFU)
Experiment 1 Day 0 Day 7 Day 90
Secondary infection: HC 6 3 105 4.6 3 102 6 0.03 3 102 ND ,10
Experiment 2 Day 0 Day 7 Day 60
Secondary infection: HC 6 3 105 ,10 8 3 102 6 0.84 3 102 ,10
Primary infection: HC 6 3 105 ND 5.3 3 106 6 0.25 3 106‡ Died
*In two independent experiments, CD40L2/2 mice were initially infected with 6 3 104 yeast cells and then reinfected (secondary infection) 3–4 wk
later with H. capsulatum (6 3 105). At the time of secondary infection (day 0), spleens of CD40L2/2 mice were assessed for H. capsulatum CFUs.
Quantitative burden of H. capsulatum was also assessed from spleens of mice at various times after secondary infection. In addition, quantitation was
done from CD40L2/2 undergoing primary infection at the same time mice were reinfected.
‡Results are statistically different (P ,0.001) from those of mice undergoing primary infection with H. capsulatum.1321 Zhou et al.
increased fungal burden, provides strong evidence that CD40L
is not required for the induction of type 1 responses after
infection with H. capsulatum. Finally, the demonstration
that all CD40L2/2 mice survived infection with a sublethal
dose of H. capsulatum (Fig. 5) but all mice treated with an
anti–IFN-g antibody had accelerated mortality and increased
fungal burden provided conclusive evidence that there is a
CD40L-independent pathway for IFN-g production.
Differential Role for CD40L in the Induction of Type 1 Cy-
tokine Production in Response to H. capsulatum and Other Intra-
cellular Infections versus L. major. The ability of CD40L2/2
mice to generate functional Th1 responses in vivo is in
contrast to the studies previously alluded to in which
CD402/2 or CD40L2/2 mice had a striking deficiency in
production of IL-12 or IFN-g after infection with L. major
or Leishmania amazonensis (17–19). Several potential mech-
anisms could account for this failure of these deficient mice
to develop functional type 1 responses in response to leish-
manial infection. One is that L. major is a relatively poor di-
rect inducer of IL-12 production or other inflammatory
mediators compared with other infectious pathogens. This
is supported by previous studies showing that Leishmania
promastigotes are able to evade or inhibit IL-12 production
(37, 38). In data not shown, we found that peritoneal mac-
rophages from CD40L2/2 mice produced comparable amounts
of IL-12, TNF-a, and NO in vitro as CD40L1/1 mice in
response to Staphylococcus aureus Cowan strain, Toxoplasma
gondii, and H. capsulatum; however, there was no induction
of these cytokines in response to L. major promastigotes (data
not shown). These data are consistent with a recent report
by DeKruyff et al. showing that heat-killed Listeria monocy-
togenes induces IL-12 production in a CD40L-independent
manner in vitro (20). In addition, the demonstration that
SCID mice infected with H. capsulatum (39), L. monocytoge-
nes (40), or T. gondii (32) all had accelerated mortality when
treated at the time of infection with anti–IL-12 provides
additional evidence that these pathogens can induce IL-12
directly or at least in the absence of T cells. Taking these
data together, we would conclude that, in addition to H.
capsulatum, L. monocytogenes and T. gondii would also induce
IL-12 in vivo independently of CD40L. Finally, it should
be noted that although L. major may be a relatively poor di-
rect inducer of IL-12, mice on a resistant C57BL/6 back-
ground develop effective immunity after infection with L.
major in an IL-12–dependent manner, suggesting additional
factors to explain the enhanced susceptibility of CD40L2/2
mice to L. major (see below).
A second mechanism to explain why CD40L2/2 mice
fail to induce IL-12 in response to L. major infection is that
this experimental model is highly reliant on MHC class II–
dependent CD4 responses for primary immunity (41–43).
Furthermore, based on in vivo (1) and in vitro (6, 20) evi-
dence showing that CD41 T cell–mediated production of
type 1 cytokines is CD40L dependent in response to pro-
tein antigens, it is possible that antigens that require CD4
and/or are relatively poor direct inducers of IL-12 (i.e., L.
major) would require CD40L for a functional IL-12 re-
sponse. This relative CD4 dependence in the Leishmania
model would be contrasted to experimental models of liste-
riosis, toxoplasmosis, and histoplasmosis in which both
CD41 and CD81 T cells have a role in primary immunity
(see below). Moreover, L. monocytogenes, T. gondii, and H.
capsulatum are all potent inducers of IFN-g from NK cells
through induction of IL-12. Thus, in these latter models,
CD81 T cells or NK cells may provide a sufficient amount
of IFN-g or other proinflammatory mediators that could help
control infection directly and/or potentiate further produc-
tion of IL-12 by a positive feedback mechanism (44, 45).
In the Absence of CD40L, CD41 or CD81 Cells Are Re-
quired for Effective Primary Immunity. As noted above, there is
evidence that CD81 T cells also play an important role in
primary immunity against a variety of intracellular patho-
gens including T. gondii (46), Mycobacterium bovis (47), My-
cobacterium tuberculosis (48), and H. capsulatum (34). It has
been shown that the ability of CD81 T cells to influence
immunity is through at least two independent mechanisms.
For secondary Listeria infection, CD81 T cells have been
shown to protect mice through a cytolytic mechanism in-
dependent of IFN-g (49, 50). By contrast, in murine mod-
els of L. monocytogenes (50), M. tuberculosis (51, 52), T. gondii
(53), or H. capsulatum infection (Zhou, P., manuscript in
preparation), primary immunity is maintained in the absence
of perforin- or granzyme-mediated cytolysis. Since IFN-g is
required for effective primary immunity to all of these in-
fections, these data suggest that IFN-g produced from
CD81 T cells is responsible for the effector function at this
phase of the response.
In the experiments reported here, CD40L2/2 mice de-
pleted of either CD41 or CD81 T cells had similar out-
comes in terms of accelerated mortality and increased fun-
gal burden after primary infection with H. capsulatum.
Explanations for these data follow. (a) There is a quantita-
tive threshold for cytokine (i.e., IFN-g) production neces-
sary for effective primary immunity in the absence of CD40L
requiring both CD41 and CD81 T cells. In preliminary
data, CD40L2/2 mice depleted of CD41 T cells at the time
of infection had markedly diminished production of IFN-g
(data not shown). (b) Depletion of either CD41 or CD81
T cells changes the qualitative cytokine response. This is
consistent with a striking enhancement of the Th1 coun-
terregulatory cytokine IL-10 noted from mice depleted of
CD41 or CD81 T cells (data not shown). (c) There are re-
cent reports showing that CD41 T cells are required for
CD81 T cell function (54, 55). This dependence on CD41
T cells could occur through modification of the antigen
presenting cell (i.e., CD40L-inducing activation and/or
cytokine production) or to provide a cytokine-rich envi-
ronment (i.e., IL-2) for the CD81 T cells. These explana-
tions may relate to the studies reported here in which the
absence of both CD41 T cells and CD40L may not pro-
vide help sufficient for CD81 T cell activation. Experi-
ments are now in progress to determine the immune
mechanism by which CD4 and CD8 depletion worsens the
course of infection in these mice.1322 CD40 Ligand Is Not Required for Th1 Responses In Vivo to Infection
CD40L Is Not Required for Secondary Immunity to H. cap-
sulatum. In a previous study, we showed that effective
primary immunity to systemic infection requires a coordi-
nated immune response requiring many factors including
IL-12, IFN-g, TNF-a, or NO. By contrast, none of these
factors alone, including IFN-g, were required for the
maintenance of immunity after secondary challenge to H.
capsulatum (26); however, treatment of mice with both
anti–IFN-g and anti–TNF-a at the time of reinfection did
result in a fatal outcome. The only studies of the role of
CD40L in memory immunity were done in experimental
murine models of viral infection. In these studies, CD40L2/2
mice had relatively normal primary CTL responses but had
markedly diminished memory responses (14). In this re-
port, CD40L2/2 mice initially infected with a sublethal
dose of H. capsulatum and then infected 3 wk later with a
lethal dose remain alive more than 90 d after infection with
no detectable H. capsulatum from spleen cells. These results
demonstrate that CD40L is not required for effective sec-
ondary immunity.
CD40L-independent Induction of Type 1 Cytokine Responses
Has Clinical Application for Infectious and Autoimmune Dis-
ease. To summarize, L. major may in fact be one of the
few intracellular infections requiring CD40–CD40L stimu-
lation for the induction of functional type 1 cytokine re-
sponses. Infection with other pathogens such as L. monocy-
togenes, T. gondii, and M. tuberculosis, which directly induce
IL-12 and/or have a role for CD81 T cells in immunity,
would not show increased susceptibility in the absence of
CD40L. This is supported by the observations in studying
patients with hyper-IgM syndrome (56). In a large review
of such patients, a minority of patients were reported to
have increased susceptibility to opportunistic infections as-
sociated with T cell deficiencies such as Pneumocystis carinii
(,10%) and Cryptosporidium (,2%), whereas there were no
cases described for other infections mediated by type 1 cel-
lular immune responses such as T. gondii, M. tuberculosis, or
H. capsulatum. These latter findings would be consistent
with the ability of these infectious pathogens to induce
type 1 cytokine responses by the mechanisms listed above.
In addition, since exogenous B7 costimulation has been
shown to restore IFN-g production in CD40L2/2 mice
(12, 13), it is possible that these various pathogens may dif-
fer in their capacity to activate accessory cells in vivo, pro-
viding a mechanism to activate T cells independently of
CD40L–CD40.
Finally, with regard to autoimmune disease, since CD40L–
CD40 stimulation has been shown to be critical for both
IL-12 production and T cell activation in response to pro-
tein antigens in vivo, inhibition of CD40L–CD40 may be a
potent treatment for certain organ-specific autoimmune
diseases. This is supported by murine models of experimen-
tal autoimmune encephalitis and inflammatory colitis in
which treatment with anti–IL-12 (57, 58) or anti-CD40L
(59, 60) was shown to ameliorate disease. One cause of
concern from chronic treatment with either of these inhib-
itors would be increased susceptibility to intracellular infec-
tion. The ability to sustain and generate an effective im-
mune response to certain intracellular pathogens independently
of CD40L may lessen this potential increase in susceptibil-
ity to these particular infections by anti–CD40L–CD40
treatment. By contrast, treatments directed at inhibiting IL-12
while ameliorating autoimmune disease could still increase
vulnerability to the aforementioned intracellular infections.
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